Lymphoma Clinical Trials & Research

The purpose of this study is to find the highest dose of the investigational drug CA-4948 that can be given safely and to evaluate its preliminary anticancer effectiveness in patients with non-Hodgkin lymphoma that has come back or continued to grow despite prior therapy. CA-4948 works by blocking a protein in normal and cancerous B cells (a type of immune cell) called IRAK4, which may promote the growth and survival of B cells in lymphoma. CA-4948 is designed to fight cancer by blocking IRAK4, thereby stopping or reducing the signals that promote lymphoma B-cell survival.

The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.   

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Cancer and its treatment can cause problems with attention, memory, and learning. These cognitive difficulties may affect your daily activities and worsen your quality of life.

Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

This study aims to obtain a better understanding of the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. Together these diseases are referred to as "lymphoproliferative disorders."

Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby's mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.